Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer

Last updated: September 17, 2019
Sponsor: Maria Sklodowska-Curie Institute - Oncology Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Rectal Disorders

Digestive System Neoplasms

Colorectal Cancer

Treatment

N/A

Clinical Study ID

NCT04095468
ORGANPRESERV1
  • Ages > 18
  • All Genders

Study Summary

Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in reporting the proportion of patients achieving clinical complete response (cCR) after routinely delivered preoperative radio(chemo)therapy, likely because of patients' selection. This proportion in population-based level is poorly defined. In addition, predictive factors for cCR are also poorly defined. It is known that cCR response is observed often in small tumours. However, cCR proportion in large cancers has not been sufficiently evaluated. For example, even though pathological complete response (pCR) does occur in large fixed cancer, it is unknown whether cCR does also occur because persistent fibrous stroma may mimic residual cancer in all of such cases.

This is a prospective observational population-based cohort study on low rectal cancer to answer the question of how often clinical or near-clinical tumour response occur after routinely delivered preoperative radiotherapy in relation to the pre-treatment tumour characteristics. The additional question was how often pCR occur in relation to the pre-treatment tumour characteristics in the patients managed by total mesorectal excision because of persistent tumour after radiotherapy. The additional aim was the implementation of watch-and-wait strategy or full-thickness local excision (as an option instead of total mesorectal excision in the patients with sustained near-cCR) within a frame of a prospective study. In the patients managed by organ preservation, the secondary outcome measures were: i) local regrowth rate, ii) effectiveness of salvage surgery, iii) disease-free survival at 3 years and overall survival at 5 years, iv) anorectal function.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Primary rectal cancer

  • Low tumour (accessible by digital rectal examination)

  • Routine preoperative radio(chemo)therapy according to the institutional policy;short-course radiation and immediate surgery is not allowed.

  • Informed consent for watch-and-wait strategy or local excision in patients with cCRand near-cCR

Exclusion

Exclusion Criteria:

  • Recurrent cancer

  • Cancers situated in the upper rectum

  • Distant metastases

Study Design

Total Participants: 215
Study Start date:
September 18, 2017
Estimated Completion Date:
January 01, 2026

Connect with a study center

  • Maria Skłodowska-Curie Institute - Oncology Center

    Warsaw, Mazovian 02-781
    Poland

    Active - Recruiting

  • Collegium Medicum Nicolaus Copernicus University and Oncology Centre

    Bydgoszcz,
    Poland

    Active - Recruiting

  • Regional Oncological Centre

    Kielce,
    Poland

    Active - Recruiting

  • Jagiellonian Medical University College

    Kraków,
    Poland

    Site Not Available

  • St. John's Cancer Center

    Lublin,
    Poland

    Active - Recruiting

  • Silesian Oncological Centre

    Wrocław,
    Poland

    Active - Recruiting

  • NU-MED Centre for Cancer Diagnosis and Treatment

    Zamość,
    Poland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.